Journal of Clinical Oncology, Vol 16, 222-228, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

High-dose carboplatin, thiotepa, and etoposide with autologous stem- cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group

IJ Dunkel, JM Boyett, A Yates, M Rosenblum, JH Garvin Jr, BC Bostrom, S Goldman, LS Sender, SL Gardner, H Li, JC Allen and JL Finlay
Memorial Sloan-Kettering Cancer Center, New York, NY, USA. dunkeli@mskcc.org

PURPOSE: Medulloblastoma is a highly lethal disease when it recurs. Very few patients survive with conventional treatment. This study evaluated the use of high-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue (ASCR) in patients with recurrent medulloblastoma. METHODS: Chemotherapy consisted of carboplatin 500 mg/m2 (or area under the curve = 7 mg/mL x min via Calvert formula) on days -8, -7, and -6; and thiotepa 300 mg/m2 and etoposide 250 mg/m2 on days -5, -4, and -3; followed by ASCR on day 0. In addition to the study-prescribed therapy, 21 patients received other treatment: neurosurgical resection in seven, conventional chemotherapy in 17, and external-beam irradiation in 11 cases. RESULTS: Twenty-three patients with recurrent medulloblastoma, aged two to 44 years (median, 13 years) at ASCR, were treated. Three patients died of treatment-related toxicities within 21 days of ASCR; multiorgan system failure in two, and Aspergillus infection with venoocclusive disease in one. Seven of 23 patients (30%) are event-free survivors at a median of 54 months post-ASCR (range, 24 to 78 months). Kaplan-Meier estimates of event- free (EFS) and overall survival are 34% +/- 10% and 46% +/- 11%, respectively, at 36 months post-ASCR. CONCLUSION: This strategy may provide long-term survival for some patients with recurrent medulloblastoma.

This article has been cited by other articles:

				B Pizer and S Clifford Medulloblastoma: new insights into biology and treatment Arch. Dis. Child. Ed. Pract., October 1, 2008; 93(5): 137 - 144. [Full Text] [PDF]

				S. Gururangan, J. Krauser, M. A. Watral, T. Driscoll, N. Larrier, D. A. Reardon, J. N. Rich, J. A. Quinn, J. J. Vredenburgh, A. Desjardins, et al. Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma Neuro-oncol, January 1, 2008; 10(5): 745 - 751. [Abstract] [Full Text] [PDF]

				S. Modak, S. Gardner, I. J. Dunkel, C. Balmaceda, M. K. Rosenblum, D. C. Miller, S. Halpern, and J. L. Finlay Thiotepa-Based High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Patients With Recurrent or Progressive CNS Germ Cell Tumors J. Clin. Oncol., May 15, 2004; 22(10): 1934 - 1943. [Abstract] [Full Text] [PDF]

				C. Pingoud-Meier, D. Lang, A. J. Janss, L. B. Rorke, P. C. Phillips, T. Shalaby, and M. A. Grotzer Loss of Caspase-8 Protein Expression Correlates with Unfavorable Survival Outcome in Childhood Medulloblastoma Clin. Cancer Res., December 15, 2003; 9(17): 6401 - 6409. [Abstract] [Full Text] [PDF]

				P. M. Magtibay, J. A. Friedman, R. D. Rao, J. C. Buckner, and W. A. Cliby Unusual presentation of adult metastatic peritoneal medulloblastoma associated with a ventriculoperitoneal shunt: A case study and review of the literature Neuro-oncol, July 1, 2003; 5(3): 217 - 220. [Abstract] [PDF]

				S. Gururangan, C. McLaughlin, J. Quinn, J. Rich, D. Reardon, E. C. Halperin, J. Herndon II, H. Fuchs, T. George, J. Provenzale, et al. High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Children and Adults With Newly Diagnosed Pineoblastomas J. Clin. Oncol., June 1, 2003; 21(11): 2187 - 2191. [Abstract] [Full Text] [PDF]

				T. J. MacDonald, B. R. Rood, M. R. Santi, G. Vezina, K. Bingaman, P. H. Cogen, and R. J. Packer Advances in the Diagnosis, Molecular Genetics, and Treatment of Pediatric Embryonal CNS Tumors Oncologist, April 1, 2003; 8(2): 174 - 186. [Abstract] [Full Text] [PDF]

				C. D. Turner, S. Gururangan, J. Eastwood, K. Bottom, M. Watral, R. Beason, R. E. McLendon, A. H. Friedman, S. Tourt-Uhlig, L. L. Miller, et al. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: The Duke experience Neuro-oncol, April 1, 2002; 4(2): 102 - 108. [Abstract] [PDF]

				M. C. Chamberlain Treatment of Intracranial Metastatic Esthesioneuroblastoma J. Clin. Oncol., January 1, 2002; 20(1): 357 - 358. [Full Text] [PDF]

				D. Strother, D. Ashley, S. J. Kellie, A. Patel, D. Jones-Wallace, S. Thompson, R. Heideman, E. Benaim, R. Krance, L. Bowman, et al. Feasibility of Four Consecutive High-Dose Chemotherapy Cycles With Stem-Cell Rescue for Patients With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor After Craniospinal Radiotherapy: Results of a Collaborative Study J. Clin. Oncol., May 15, 2001; 19(10): 2696 - 2704. [Abstract] [Full Text] [PDF]

				O. Rick, C. Bokemeyer, J. Beyer, J. T. Hartmann, N. Schwella, D. Kingreen, S. Neureither, B. Metzner, J. Casper, H. Wandt, et al. Salvage Treatment With Paclitaxel, Ifosfamide, and Cisplatin Plus High-Dose Carboplatin, Etoposide, and Thiotepa Followed by Autologous Stem-Cell Rescue in Patients With Relapsed or Refractory Germ Cell Cancer J. Clin. Oncol., January 1, 2001; 19(1): 81 - 88. [Abstract] [Full Text] [PDF]